Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 48.63M | 35.88M | 35.17M | 31.84M | 30.73M |
| Gross Profit | -48.63M | -35.88M | -35.17M | -31.84M | -30.73M |
| SG&A Expenses | 14.67M | 13.14M | 11.91M | 10.30M | 9.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.04M | 44.60M | 37.51M | 32.57M | 31.11M |
| Operating Income | -50.04M | -44.60M | -37.51M | -32.57M | -31.11M |
| Income Before Tax | -46.36M | -41.63M | -35.39M | -31.37M | -30.04M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -46.36 | -41.63 | -35.39 | -31.37 | -30.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.36M | -41.63M | -35.39M | -31.37M | -30.04M |
| EBIT | -50.04M | -44.60M | -37.51M | -32.57M | -31.11M |
| EBITDA | -49.70M | -44.26M | -37.21M | -32.31M | -30.88M |
| EPS Basic | -0.88 | -1.08 | -1.26 | -1.46 | -1.59 |
| Normalized Basic EPS | -0.55 | -0.67 | -0.79 | -0.91 | -0.99 |
| EPS Diluted | -0.88 | -1.08 | -1.26 | -1.46 | -1.59 |
| Normalized Diluted EPS | -0.55 | -0.67 | -0.79 | -0.91 | -0.99 |
| Average Basic Shares Outstanding | 224.18M | 178.91M | 133.06M | 87.70M | 75.80M |
| Average Diluted Shares Outstanding | 224.18M | 178.91M | 133.06M | 87.70M | 75.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |